Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-PCSSC dose-ranging placebo-controlled trial in high cardiovascular risk patients with elevated LDL cholesterol
NL-OMON43890Phase 2Active, not recruiting
- Sponsor
- The Medicines Company
- Start
- Jan 2016
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atherosclerosis, hypercholesterolemia, familial hypercholesterolemia (FH) and 1 more comparing ALN-PCSSC with Placebo (2 arms). Primary endpoint: LDL cholesterol at Day 180. Started Jan 2016; status: active, not recruiting.
02
Drugs
inclisiran
03
Conditions
atherosclerosishypercholesterolemiafamilial hypercholesterolemia (FH)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON43890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43890.